Download PDF
Thromb Haemost 1988; 60(03): 434-436
DOI: 10.1055/s-0038-1646985
Original Article
Schattauer GmbH Stuttgart

Heparin and Bleeding: An Association with Lipase Release

T W Barrowcliffe
1   The National Institute for Biological Standards and Control, London, UK
,
R E Merton
1   The National Institute for Biological Standards and Control, London, UK
,
E Gray
1   The National Institute for Biological Standards and Control, London, UK
,
D P Thomas
1   The National Institute for Biological Standards and Control, London, UK
› Author Affiliations
Further Information

Publication History

Received 20 May 1988

Accepted after revision 21 July 1988

Publication Date:
30 June 2018 (online)

Also available at
  PDF Download Permissions and Reprints

Summary

The effects of four sulphated polysaccharides on bleeding time and lipase release in rabbits have been compared. Unfractionated heparin (UFH) and pentosan polysulphate both gave significant prolongation of bleeding times and high lipase release. Low molecular weight heparin had reduced effects on bleeding time and lipase release, while demialan sulphate had no influence on either parameter. There was a highly significant correlation (r = 0.97) between these two measurements.

These results suggest that the same structural featuresinfluence both the haemorrhagic and lipase-releasing properties of sulphated polysaccharides.

Keywords

Heparin - Lipase - Haemorrhage
 

  • References

  • 1 Salzman EW. Low molecular weight heparin - is small beautiful?. N Engl J Med 1986; 315: 957-959
    CrossrefPubMedSearch in Google Scholar
  • 2 Thomas DP. Current status of low molecular weight heparin. Thromb Haemostas 1986; 56: 241-242
    PubMedSearch in Google Scholar
  • 3 Andersson L-O, Barrowcliffe TW, Holmer EA, Johnson EA, Sims GE C. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575-583
    CrossrefPubMedSearch in Google Scholar
  • 4 Barrowcliffe T W, Johnson EA, Eggleton CA, Kemball-Cook G, Thomas DP. Anticoagulant activities of high and low molecular weight heparin fractions. Br J Haematol 1979; 41: 573-583
    CrossrefPubMedSearch in Google Scholar
  • 5 Thomas DP. Heparin in the prophylaxis and treatment of venous thrombosis. Semin Haematol 1978; 15: 1-17
    PubMedSearch in Google Scholar
  • 6 Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin and heparin. Blood 1982; 59: 1239-1245
    PubMedSearch in Google Scholar
  • 7 Esquivel GO, Bergqvist D, Björk CG, Nilsson B. Comparison between commercial heparin, low-molecular-weight heparin andpentosan polysulphate on hemostasis and platelets in vivo. Thromb Res 1982; 8: 389-399
    PubMedSearch in Google Scholar
  • 8 Cade JF, Buchanan MR, Boneu B, Ockelford P, Carter CJ, Cerskus AL, Hirsh J. A comparison of the antithrombotic and haemorrhagic. Effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 1984; 35: 613-625
    CrossrefPubMedSearch in Google Scholar
  • 9 Schmitz-Huebner U, Bünte H, Freise G, Reers B, Rüschmeyer C, Scherer R, Schulte H, van de Loo J. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. Klin Wochenschr 1984; 62: 349-353
    CrossrefPubMedSearch in Google Scholar
  • 10 Koller M, Schoch U, Buchmann P, Largiadèr F, von Felten A, Frick PG. Low molecular weight heparin (Kabi 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin. Thromb Haemostas 1986; 56: 243-246
    PubMedSearch in Google Scholar
  • 11 Bergqvist D, Burmark US, Frisell J, Hallibook I, Lundblad B, Risberg B, Torngren S, Wallin G. Low molecular weight heparin once daily compared with conventional low dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg 1986; 73: 204-208
    CrossrefPubMedSearch in Google Scholar
  • 12 Kakkar VV, Murray WJ G. Efficacy and safety of low-molecular-weight heparin (CY 216) in preventing postoperative venous thromboembolism: a cooperative study. Br J Surg 1985; 72: 786-791
    CrossrefPubMedSearch in Google Scholar
  • 13 Persson E, Nordenström J, Nilsson-Ehle P, Hagenfeldt L. Lipolytic and anticoagulant activities of a low molecular weight fragment of heparin. Eur J Clin Invest 1985; 15: 215-220
    CrossrefPubMedSearch in Google Scholar
  • 14 Barrowcliffe TW, Gray E, Merton RE, Dawes J, Jennings CA, Hubbard AR, Thomas DP. Anticoagulant activities of pentosan polysulphate (Hèmoclar) due to release of hepatic triglyceride lipase (HTGL). . Thromb Haemostas 1986; 56: 202-206
    PubMedSearch in Google Scholar
  • 15 Gray E, Bengtsson-Olivecrona G, Olivecrona T, Barrowcliffe TW. Anti-Xa activity of human hepatic triglyceridelipase. J Lab ClinMed 1987; 109: 653-659
    PubMedSearch in Google Scholar
  • 16 Johnson EA, Paterson MS. Lead precipitation: an aid to separation of dermatan and mucokeratan sulfates from glycosaminoglycan mixtures. Anal Biochem 1986; 158: 111-116
    CrossrefPubMedSearch in Google Scholar
  • 17 Merton RE, Thomas DP. Experimental studies on the relative effectiveness of dermatan sulphateand heparin as antithrombotic agents. Thromb Haemostas 1987; 58: 839-842
    PubMedSearch in Google Scholar
  • 18 Nilsson-Ehle P, Schotz MC. A stable radioactive substrate emulsion for the assay of lipoprotein lipase. J Lipid Res 1976; 17: 536-541
    PubMedSearch in Google Scholar
  • 19 Williams SP, Barrowcliffe TW. The effects of post-heparin plasma lipases on anti-Xa clotting activity. Thromb Res 1985; 37: 371-377
    CrossrefPubMedSearch in Google Scholar
  • 20 Proctor RR, Rapaport SI. A partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961; 36: 121-129
    PubMedSearch in Google Scholar
  • 21 Thomas DP, Merton RE. A low molecular weight heparin compared with unfractionated heparin. Thromb Res 1982; 28: 343-350
    CrossrefPubMedSearch in Google Scholar
  • 22 Pangrazzi J, Abbadini M, Zametta M, Casu B, Donati MB. Low molecular weight heparins and bleeding. Thromb Haemostas 1985; 53: 158
    PubMedSearch in Google Scholar
  • 23 Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favrean L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73
    CrossrefPubMedSearch in Google Scholar
  • 24 Brace LD, Fareed L. Heparin-induced platelet aggregation: dose/ response relationships for a low molecular weight heparin derivate (PK 10169) and its subfractions. Thromb Res 1986; 42: 769-782
    CrossrefPubMedSearch in Google Scholar
  • 25 Westwick J, Scully MF, Poll C, Kakkar VV. Comparison of the effects of low-molecular-weight heparin and unfractionated heparin on activation of human platelets in vitro. Thromb Res 1986; 42: 435-447
    CrossrefPubMedSearch in Google Scholar
  • 26 Holmer E, Lindahl U, Bäckström G, Thunberg LK, Sandberg H, Söderström G, Andersson L-O. Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for anti-thrombin. Thromb Res 1980; 18: 861-869
    CrossrefPubMedSearch in Google Scholar
  • 27 Van Ryn-McKenna J, Ofosu FA, Johnson EA, Hirsh J, Buchanan MR. Increased sulfation increases the bleeding side-effects of gly-cosaminoglycans. Thromb Haemostas 1987; 58: 57
    PubMedSearch in Google Scholar
  • 28 Borowska A, Lauri D, Dejana E, deGaetano G, Donati MB, Pangrazzi J. Impairment of primary haemostasis by low molecular weight-heparins in rats. Br J Haematol 1988; 68: 339
    CrossrefPubMedSearch in Google Scholar